The tariffs are Trump’s way of getting drug companies to move more of their operations to the U.S. at a time when domestic drug manufacturing has declined. Eli Lilly has been quick to comply, announcing plans to invest at least $27 billion to build four new manufacturing sites across America.

President Donald Trump is ratcheting up the pressure on major drugmakers to bring their US prices in line with the far lower ones available to patients in other countries — though industry experts don’t expect the pharmaceutical companies to acquiesce.